Skip to main content

Table 3 Best corrected visual acuity (BCVA) improvement in patients with chronic or recurrent central serous chorioretinopathy after different doses of photodynamic therapy

From: One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy

BCVA improvement (LogMAR)

Half dose (mean±SD)

One-third dose (mean±SD)

P-value a

VA 1 month - VA Initial

−0.09±0.26

− 0.04±0.13

0.317

VA 3 month - VA Initial

−0.11±0.27

− 0.05±0.15

0.244

VA 6 month - VA Initial

−0.16±0.30

− 0.09±0.14

0.161

VA 12 month - VA Initial

−0.17±0.29

− 0.10±0.17

0.148

  1. a Linear fixed- and random-effects models
  2. Abbreviations: BCVA best corrected visual acuity, LogMAR logarithm of the minimum angle of resolution;
  3. SD standard deviation
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us